NVSEF - Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

2024-02-11 04:27:27 ET

Summary

• Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024.
• The company is also progressing with the phase 3 SOL study for wet age-related macular degeneration using AXPAXLI, its axitinib intravitreal implant; First patient to be dosed Q1 of 2024.
• Patient compliance with ocular disorder treatment could be improved. The hope is that the company's extended-release hydrogel technology Elutyx can greatly reduce the need for frequent injections.
• Results from the phase 2 randomized study, using PAXTRAVA for patients with open-angle ocular glaucoma and ocular hypertension, are expected at ASCRS meeting in April of 2024.

Ocular Therapeutix ( OCUL ) has been making extensive progress in being able to advance the use of its Elutyx technology to advance several drug candidates to treat patients with eye disorders. The reason why I think investors may want to take a look into this biotech is because it is gearing up to report results from the phase 1/2 HELIOS study, using AXPAXLI for the treatment of patients with diabetic retinopathy. It is expected that preliminary nine-month results from this early-stage study are going to be released Q2 of 2024. This sets up a major catalyst for investors to look forward to. In addition, to the fact that it could provide additional proof of mechanism of action [MOA] in being able to use its Elutyx technology to treat ocular disorders....

For further details see: